EQT life science
EQT Life Science develops medications, devices, and methods to combat it.
Business Model:
Revenue: $42.9M
Employees: 11-50
Rankings
Industries / Tags:
Detailed EQT life science Information
EQT life science was acquired by
EQT.
The acquisition happend on 2021-11-10.
Details of the transaction were not public
Acquirer
Geographic Data
Address: Johannes Vermeerplein 9
City: Amsterdam
State: noord-holland
Zip: 1071 DV
Country: NL
Financial Info
Stage:
Raised Last:
$0
Raised Total:$3B
Social
Linkedin
Crunchbase
Metrics
4,837,703Website Global Rank
2,148Website Monthly Traffic
Twitter Followers
Description
EQT life science develops innovative medicines, devices and tools to address the single most important thing that matters to all the preservation of health. The organization believes that such opportunities add value to all stakeholders.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 5/2016 | Nouscom | Series A | 13.6M |
| 11/2017 | Xeltis | Series C | 53M |
| 12/2007 | Vivendy Therapeutics | Series A | 15.4M |
| 5/2008 | Asoyia | Venture Round | 4M |
| 2/2022 | Perfuze | Series A | 0 |
| 4/2014 | Heart Metabolics | Series A | 20M |
| 7/2021 | Artios Pharma | Series C | 0 |
| 2/2009 | ActoGeniX | Private Equity Round | 17.4M |
| 2/2007 | ActoGeniX | Venture Round | 26.1M |
| 7/2019 | AM Pharma | Series F | 130.1M |
| 1/2019 | INNOVO by Atlantic Therapeutics | Series B | 32.1M |
| 11/2012 | Kiadis Pharma | Venture Round | 0 |
| 7/2001 | NewBiotics | Series C | 0 |
| 9/2016 | Vivasure Medical | Series C | 18.3M |
| 9/2017 | Immunic Therapeutics | Series A | 11.9M |
| 2/2006 | EyeSense AG | Series A | 0 |
| 2/2023 | Xeltis | Series D | 0 |
| 8/2022 | eTheRNA immunotherapies | Series B | 0 |
| 6/2022 | Ariceum Therapeutics | Series A | 0 |
| 12/2021 | ViCentra | Series C | 0 |
| 3/2010 | Seahorse Bioscience | Series D | 5M |
| 10/2015 | Sequana Medical | Series C | 0 |
| 8/2021 | Visus Therapeutics | Equity | 20M |
| 6/2020 | OneProjects | Series A | 12.4M |
| 1/2010 | Harvest Automation | Series A | 4M |
| 1/2007 | 4-Antibody AG | Series A | 18.4M |
| 10/2012 | Cobalt Technologies | Venture Round | 5M |
| 3/2019 | SNIPR Biome | Series A | 50M |
| 12/2014 | Xeltis | Series B | 33.5M |
| 4/2005 | DNage | Series A | 1.9M |
| 1/2016 | Pharvaris | Series A | 16.3M |
| 4/2006 | Pronota | Series A | 7.8M |
| 1/2010 | Merus | Series B | 0 |
| 4/2012 | Cobalt Technologies | Venture Round | 2.9M |
| 1/2005 | OctoPlus | Series B | 23.9M |
| 5/2018 | Rainier Therapeutics | Series B | 20M |
| 2/2007 | Prosensa | Series A | 18M |
| 9/2010 | Harvest Automation | Series A | 1.3M |
| 10/2013 | Harvest Automation | Series C | 11.8M |
| 5/2003 | Santarus | Series D | 51.4M |
| 7/2017 | Simplify Medical | Series B | 21M |
| 2/2018 | Simplify Medical | Series B | 23M |
| 3/2007 | Okairos | Series A | 9.6M |
| 11/2009 | Kreatech Diagnostics | Venture Round | 0 |
| 10/2007 | Hyperion Therapeutics | Debt Financing | 15M |
| 9/2007 | Nexstim | Venture Round | 10.9M |
| 4/2016 | Onward | Series A | 29.5M |
| 10/1999 | Devgen | Series B | 24.7M |
| 1/2012 | Pronota | Series C | 4.8M |
| 1/2007 | Movetis | Series A | 63.8M |
| 2/2010 | arGEN-X | Series A | 4.5M |
| 7/2020 | DNA Script | Series B | 50M |
| 12/2006 | BMEYE | Series A | - |
| 8/2015 | Kuros Biosciences | Post-IPO Equity | 15.3M |
| 7/2002 | Scion Pharmaceuticals | Series B | 0 |
| 7/2003 | PamGene | Series B | 11.3M |
| 8/2006 | Pronota | Series A | 10.6M |
| 5/2021 | Binx Health | Series E | 0 |
| 7/2019 | Amolyt Pharma | Series A | 0 |
| 11/2014 | Curetis | Series B | 0 |
| 10/2012 | Affimed | Series D | 20.1M |
| 6/2011 | Sapiens Steering Brain Stimulation | Series A | 18.7M |
| 11/2009 | Vivoryon Therapeutics | Series B | 0 |
| 1/2012 | Vivoryon Therapeutics | Venture Round | 19.4M |
| 10/2021 | DNA Script | Series C | 0 |
| 12/2018 | XyloCor Therapeutics | Series A | 17M |
| 8/2007 | BioProcessors | Series C | 10M |
| 4/2007 | Affimed | Series B | 32M |
| 1/2021 | Neurent Medical | Series B | 0 |
| 8/2016 | Rotation Medical | Series B | 12M |
| 7/2014 | Rotation Medical | Series B | 27.2M |
| 1/2012 | Prosensa | Venture Round | 0 |
| 7/2009 | Pasteuria Bioscience | Series B | 0 |
| 6/2015 | Neuravi | Series B | 21.5M |
| 3/2021 | XyloCor Therapeutics | Series A | 0 |
| 10/2007 | Syntaxin | Series B | 32M |
| 12/2009 | Curetis | Series A | 27.9M |
| 2/2019 | Arvelle Therapeutics | Series A | 0 |
| 12/2000 | PamGene | Series A | 6.2M |
| 10/2021 | OneProjects | Series A | 8M |
| 5/2023 | VarmX | Series B | 0 |
| 2/2018 | Merus | Post-IPO Equity | 55.8M |
| 6/2007 | Kiadis Pharma | Venture Round | 0 |
| 7/2021 | Xilis | Series A | 0 |
| 9/2019 | Nkarta Therapeutics | Series B | 114M |
| 12/2021 | AviadoBio | Series A | 0 |
| 7/2020 | ViCentra | Venture Round | 0 |
| 9/2012 | IlluminOss Medical | Series C | 0 |
| 11/2009 | Trinity Biosystems | Debt Financing | 7.5M |
| 3/2015 | Cardiac Dimensions | Equity | 15.2M |
| 7/2011 | Binx Health | Series B | 27.1M |
| 10/2013 | Merus | Series B | 42.2M |
| 1/2017 | Binx Health | Series D | 0 |
| 3/2023 | QurAlis | Series B | 0 |
| 12/2015 | Xeltis | Series B | 3.3M |
| 10/2008 | Cobalt Technologies | Series C | 0 |
| 4/2015 | Merus | Series C | 79.1M |
| 9/2018 | Endotronix | Series D | 0 |
| 9/2020 | Cardiac Dimensions | Series C | 17.5M |
| 3/2016 | eTheRNA immunotherapies | Series A | 26.6M |
| 8/2021 | T-knife | Series B | 110M |
| 5/2017 | ImCheck Therapeutics | Series A | 21.9M |
| 5/2017 | Cardior Pharmaceuticals | Series A | 16.3M |
| 10/2021 | Egle Therapeutics | Series A | 0 |
| 3/2004 | 4-Antibody AG | Seed Round | 2.1M |
| 5/2012 | Celladon | Venture Round | 10M |
| 5/2003 | BioXell | Series B | 19.9M |
| 7/2020 | Vico Therapeutics | Series A | 31M |
| 8/2016 | Mint Solutions | Series B | 5.6M |
| 7/2014 | Mint Solutions | Series A | 6M |
| 4/2021 | Onward | Venture Round | 0 |
| 4/2020 | FoRx Therapeutics | Seed Round | 10.8M |
| 11/2017 | Orphazyme | Post-IPO Equity | 0 |
| 12/2019 | ImCheck Therapeutics | Series B | 53.2M |
| 11/2009 | Cellerix | Series B | 40.5M |
| 9/2007 | Cellerix | Series B | 37.2M |
| 4/2023 | Evommune | Series B | 50M |
| 4/2014 | Binx Health | Series B | 0 |
| 3/2017 | Rainier Therapeutics | Series B | 30M |
| 7/2020 | VarmX | Series B | 36.3M |
| 11/2016 | OxThera | Series D | 34.1M |
| 1/2010 | Cellerix | Series C | 37.7M |
| 11/2021 | HotSpot Therapeutics | Series C | 0 |
| 1/2016 | Rainier Therapeutics | Series A | 13M |
| 1/2010 | Kreatech Diagnostics | Series B | 0 |
| 8/2021 | Cardior Pharmaceuticals | Series B | 0 |
| 1/2016 | ViCentra | Series B | 10.9M |
| 4/2020 | Kiadis Pharma | Post-IPO Equity | 5.5M |
| 6/2011 | Mendor | Series B | 11.7M |
| 5/2020 | Arvelle Therapeutics | Series A | 0 |
| 9/2014 | Affimed | Series E | 0 |
| 9/2016 | Immunic Therapeutics | Series A | 19.6M |
| 8/2007 | FlowCardia | Series C | 0 |
| 2/2010 | Promethera Biosciences | Series A | 7.3M |
| 11/2003 | Affectis Pharmaceuticals | Series A | - |
| 11/2011 | Harvest Automation | Series B | 7.9M |
| 4/2000 | NewBiotics | Venture Round | 6.3M |
| 1/2023 | Amolyt Pharma | Series C | 0 |
| 8/2007 | Isto Technologies | Series E | 0 |
| 9/2021 | Amolyt Pharma | Series B | 0 |
| 8/2018 | Artios Pharma | Series B | 0 |
| 5/2011 | Cobalt Technologies | Series D | 0 |
| 10/2015 | Luxendo | Series A | 0 |
| 1/2011 | Nexstim | Venture Round | 0 |
| 6/2009 | Pronota | Series B | 7.4M |
| 9/2019 | Pharvaris | Series B | 66M |
| 1/2009 | BMEYE | Series A | - |
| 4/2004 | NewBiotics | Series E | 4.6M |
| 7/2020 | Cybin | Series B | 0 |
| 3/2014 | Hybrigenics | Post-IPO Equity | 8.4M |
| 5/2019 | DNA Script | Series B | 38.5M |
| 6/2022 | ImCheck Therapeutics | Series C | 0 |
| 4/2023 | Evommune | Series B | 0 |
| 3/2023 | QurAlis | Series B | 0 |
| 2/2023 | Xeltis | Series D | 0 |
| 1/2023 | Amolyt Pharma | Series C | 0 |
| 8/2022 | eTheRNA immunotherapies | Series B | 0 |
| 6/2022 | ImCheck Therapeutics | Series C | 0 |
| 6/2022 | Ariceum Therapeutics | Series A | 0 |
| 2/2022 | Perfuze | Series A | 0 |
| 12/2021 | ViCentra | Series C | 0 |
| 12/2021 | AviadoBio | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
